Drugs / Lunbotinib
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05443126 | Sep 2022 → Mar 2027 expected | non-small cell lung carcinoma | Ellipses Pharma | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lunbotinib | “The aim of this study is to assess the safety, side effects and effectiveness of EP0031 (Lunbotinib) in patients with advanced RET-altered non-small cell lung cancer (NSCLC) in...” NCT05443126 ↗ |
| Known as | EP0031 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05443126 ↗ |
| Action | Inhibit | “EP0031 is a potent and selective RET inhibitor” NCT05443126 ↗ |
| Modality | Small molecule | — CHEMBL6068136 ↗ |
| Route | Oral | “EP0031 capsules at the recommended dose, taken once daily” NCT05443126 ↗ |
| Target | RET | “EP0031 is a potent and selective RET inhibitor” NCT05443126 ↗ |